Quantitative HLA‐class‐II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A-Reference-Cited by-同舟云学术

Quantitative HLA‐class‐II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A

Published:2020-01 Issue:1 Volume:18 Page:201-216
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Diego Vincent P.¹²,Luu Bernadette W.¹²³,Hofmann Marco⁴,Dinh Long V.³,Almeida Marcio¹²,Powell Jerry S.⁵,Rajalingam Raja⁶,Peralta Juan M.¹²,Kumar Satish¹²,Curran Joanne E.¹²,Sauna Zuben E.⁷,Kellerman Roberta⁸,Park Yara⁹,Key Nigel S.⁸⁹,Escobar Miguel A.¹⁰,Huynh Huy¹¹,Verhagen Anne M.¹¹,Williams‐Blangero Sarah¹²,Lehmann Paul V.¹²¹³¹⁴,Maraskovsky Eugene¹¹,Blangero John¹²,Howard Tom E.¹²³¹⁵

Affiliation:

1. South Texas Diabetes and Obesity Institute University of Texas Rio Grande Valley Brownsville Texas

2. Department of Human Genetics School of Medicine University of Texas Rio Grande Valley Brownsville Texas

3. Haplogenics Corporation Brownsville Texas

4. CSL Behring GmbH, Research Marburg Germany

5. CSL Behring, Med Affairs King of Prussia Pennsylvania

6. Immunogenetics and Transplantation Laboratory Department of Surgery School of Medicine University of California at San Francisco California

7. Hemostasis Branch Division of Plasma Protein Therapeutics Office of Tissues and Advanced Therapeutics Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland

8. Division of Hematology Department of Medicine University of North Carolina at Chapel Hill North Carolina

9. Department of Laboratory Medicine and Pathology University of North Carolina at Chapel Hill North Carolina

10. Division of Hematology Department of Medicine McGovern School of Medicine University of Texas Health Sciences Center at Houston Texas

11. CSL Limited Research Bio21 Institute Melbourne Australia

12. Department of Pathology Case Western Reserve University School of Medicine Cleveland Ohio

13. Department of Neurology Case Western Reserve University School of Medicine Cleveland Ohio

14. Cellular Technology Ltd Shaker Heights Ohio

15. Department of Pathology and Lab Medicine VA Valley Coastal Bend Healthcare Center Harlingen Texas

Funder

CSL Behring

National Heart, Lung, and Blood Institute

National Center for Research Resources

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14647

Reference75 articles.

1. Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors

2. Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX

3. The Multifactorial Etiology of Inhibitor Development in Hemophilia: Genetics and Environment

4. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis

5. Impact of polymorphisms of the major histocompatibility complex classÂ II, interleukin-10, tumor necrosis factor-Î± and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophiliaÂ A

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics;Pharmaceutics;2022-12-01

2. Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays;mAbs;2021-12-20